Venclexta (venetoclax)

Numéro de dossier de l’APP: 21561
État des négociations:
Active Negotiation
Indication(s):
in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
Promoteur/fabricant:
AbbVie Corporation
Numéro de projet de l’ACMTS:
PC0238-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Not Applicable